BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Biosign Technologies Inc. Receives FDA Pre-Market Clearance for Biosign Pulsewave™ Monitor


12/4/2012 7:49:32 AM

TORONTO , Dec. 4, 2012 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) (the "Company") is very pleased to announce that it has received official notification from the US Food & Drug Administration, confirming that the Company's UFIT TEN-10, now branded the Biosign Pulsewave™ Monitor, has been granted Section 510(k) clearance for sale in the United States .

The specific wording of the 510(k) clearance is as follows: "The UFIT•TEN•10 Automated Wrist Blood Pressure Monitor with Computer Controls and Web Services is a non-invasive blood pressure measurement system intended to measure the systolic and diastolic blood pressure and pulse rate. It is intended for patient use at home and by healthcare professionals in their respective practice. The device is intended for use by adults 18 years or older. The cuff is to be used for wrist sizes from 13.5 cm to 23 cm (5.3 in to 9.1 in)."

This critical regulatory approval clears the way for sales of the Pulsewave™ Monitor product line to both Healthcare Providers and Consumers in the world's largest market for medical devices. As a computerized blood pressure monitor, Pulsewave™ will compete with other automated, clinical grade BP monitoring products. Frost & Sullivan estimates that by 2015, the total US Market for BP monitors will exceed $1.1 billion , split between approximately $300 million in the professional market and approximately $800 million in the home market [source: "Assessment of North American and European Markets for Blood Pressure Monitoring and Telehealth" Frost & Sullivan, April 8 , 2011]. As a primarily software-driven Cloud Diagnostics™ solution, the Pulsewave™ system is uniquely positioned to compete successfully in both arenas, since results can be customized for each audience.

Biosign CEO Robert Kaul stated: "This regulatory approval is a cornerstone to our 2013 sales plan. With this announcement, our Pulsewave™ system now has regulatory approval for Canada , the European Union and the United States , which will represent a total combined market of over $1.7 billion by 2015 [source: Frost & Sullivan, April 8, 2011 report]. Our goal now is to capitalize on our distribution relationships in all three regions to meet our corporate sales requirements in 2013 and beyond."

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Biosign Technologies Inc.

Contact:

Biosign Contact Information

Robert Kaul

Chief Executive Officer

Biosign Technologies

Phone: (416) 218-9800 ext. 201

Email: ceo@biosign.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES